USFDA issues three observations each on API, Finished Product side of Lupin Pithampur facility
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-09-28 06:45 GMT | Update On 2024-09-28 11:26 GMT
Advertisement
Mumbai: Lupin has announced that the United States Food and Drug Administration (USFDA) has issued three observations each on the API and Finished Product side of the Company's Pithampur facility.
The facility was inspection from September 16 to September 27, 2024.
"We are addressing the observations comprehensively and will respond to the U.S. FDA within the stipulated timeframe," the Company stated in a BSE filing.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.